CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cellsTobias Bexte, Evelyn Ullrich, Jamal Alzubi et al.|Nature Communications|2024Cited by 71
CRISPR/Cas9 Gene Editing of Immune Checkpoint Receptor NKG2A Improves the Efficacy of Primary CD33-CAR-NK Cells Against AMLNawid Albinger, Evelyn Ullrich, Tobias Bexte et al.|Blood|2022Cited by 22
High antileukemic efficiency of CD19-CAR NK cells engineered with Sleeping Beauty transposon vectorsTobias Bexte, Evelyn Ullrich, Lacramioara Botezatu et al.|Klinische Pädiatrie|2022Cited by 0